For: | Huan HB, Lau WY, Xia F, Ma KS, Bie P. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma. World J Gastroenterol 2014; 20(39): 14505-14509 [PMID: 25339839 DOI: 10.3748/wjg.v20.i39.14505] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i39/14505.htm |
Number | Citing Articles |
1 |
Linda Calistri, Cesare Cordopatri, Cosimo Nardi, Elena Gianni, Fabio Marra, Stefano Colagrande. Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Molecular and Clinical Oncology 2017; 6(3): 389 doi: 10.3892/mco.2017.1132
|
2 |
Mehran Afshar, Peter Fletcher, Antonio D Bardoli, Yuk Ting Ma, Pankaj Punia. Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort. Oncotarget 2018; 9(24): 16988 doi: 10.18632/oncotarget.24769
|
3 |
Rebekah R. White, Vijay G. Menon. Principles and Practice of Geriatric Surgery. 2020; : 855 doi: 10.1007/978-3-319-47771-8_57
|
4 |
Shruthi Kanthaje, Ankita Makol, Anuradha Chakraborti. Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks. Hepatology Research 2018; 48(1): 5 doi: 10.1111/hepr.12991
|
5 |
Rebekah R. White, Vijay G. Menon. Principles and Practice of Geriatric Surgery. 2017; : 1 doi: 10.1007/978-3-319-20317-1_57-1
|
6 |
Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, Kuniaki Fukuda, Ichinosuke Hyodo. A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy. Clinical Journal of Gastroenterology 2020; 13(5): 902 doi: 10.1007/s12328-020-01154-z
|
7 |
Jing Hu, Jing Zhang, Feifei Sun, Mei Qi, Peng Su, Hui Liu, Lin Gao, Meng Jiao, Zhen Wu, Lei Xiang, Bo Han. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor. Anti-Cancer Drugs 2019; 30(7): 677 doi: 10.1097/CAD.0000000000000746
|